Halozyme Therapeutics announced the pricing of $1.3 billion in 1.50% convertible senior notes due 2033, increasing from an initial $1.05 billion offering. The proceeds will partly fund repurchases of existing convertible notes due in 2027 and 2028, totaling about $652.5 million, and support general corporate purposes including working capital and potential acquisitions. The notes offer a conversion premium of approximately 27.5% over the current stock price and include capped call transactions to reduce dilution. The offering is expected to close on September 22, 2026, and aims to strengthen the company's financial position for future growth.
Halozyme Therapeutics' convertible senior notes pricing is reported with Pluang's Health-sector market data as of Sep 18, 2026 10:31 WIB. For readers following Health-sector stocks, 63 of 91 priced US stocks rose and 28 fell today. Notable movers include Sana Biotechnology Inc (SANA) at USD 3.17 with a 1-day change of +8.56% and Pluang order activity of 29% Sell / 71% Buy, 10X Genomics Inc (TXG) at USD 77.99 with a 1-day change of +7.31% and 0% Sell / 100% Buy order activity, and DENTSPLY SIRONA Inc (XRAY) at USD 9.41 with a 1-day change of -7.20% and 100% Sell / 0% Buy order activity. The most notable figure is TXG's 100% Buy order activity.
The Reserve Bank of Australia (RBA) governor Michele Bullock warned that inflation risks are increasing due to rising oil prices, the Middle East conflict, and a global AI investment boom. These factors are pushing up costs and could embed inflation ...
XRP Ledger developers launched version 3.4.0, introducing two amendment packages: LendingProtocolV1_1 for closed-ended vaults and cash-basis accounting, and fixCleanup3_4_0, which includes multiple transaction and security fixes. While these amendmen...
Hyperliquid's trading volume drives growth in its HYPE token burn mechanism, with weekly protocol revenue reaching $13.48 million and gross fees at $15.11 million. This revenue helped remove 156.58K HYPE tokens worth about $12.42 million, contributin...
Wacker Chemie AG presented its growth strategy during an investor day, highlighting its strong market positions in silicones, polymers, biosolutions, and polysilicon. The company is the global leader or a top player in these specialized chemical mark...
Alibaba's stock fell 18% after missing Q1 earnings expectations, but this selloff is seen as overdone, leading to an upgrade to Strong Buy. The company's AI Cloud revenue surged 45% year-over-year, with expectations to maintain over 40% growth and im...
